MedPath

Glucose-Dependent Insulinotropic Polypeptide - Effects on Markers of Bone Turnover in Patients With Type 1 Diabetes

Not Applicable
Completed
Conditions
Type 1 Diabetes Mellitus
Interventions
Other: Saline
Other: GLP-1
Other: GIP
Registration Number
NCT03195257
Lead Sponsor
Mikkel Christensen
Brief Summary

Investigate GIP effects on biomarkers involved in bone homeostasis

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
10
Inclusion Criteria
  • Patients with type 1 diabetes (positive islet cell/ glutamic acid decarboxylase-65 antibodies)
  • Patients without measurable beta cell function (i.e. incremental C-peptide below detection limit (<0.16 nmol/l) following an 5 g-iv-arginine stimulation test,
Exclusion Criteria
  • HbA1c >9% (75 mmol/mol),
  • standard plasma biochemical measurements outside normal reference interval (alanine aminotransferase, bilirubin, thyroid-stimulating hormone, hemoglobin, creatinine, and spot urine albumin-creatinine ratio);
  • an abnormal state of hypoglycemia awareness,
  • significant diabetic complications (i.e. proliferative diabetic retinopathy, neuropathy, severe atherosclerosis, heart disease) and,
  • treatment with medication (besides insulin) that could not be paused for 12 hours up to and during the days of the experiments.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Hypoglycemia-salineSaline-
Hypoglycemia-GLP-1GLP-1-
Hypoglycemia-GIPGIP-
Hyperglycemia-GIPGIP-
Hyperglycemia-SalineSaline-
Primary Outcome Measures
NameTimeMethod
C-terminal telopeptide of type I collagen (CTX).30 minutes intervals, time 0 up to 120 min
Secondary Outcome Measures
NameTimeMethod
N-terminal propeptide of type 1 procollagen (P1NP).30 minutes intervals, time 0 up to 120 min
Parathyroid hormone (PTH)30 minutes intervals, time 0 up to 120 min
© Copyright 2025. All Rights Reserved by MedPath